Oppenheimer analyst Hartaj Singh maintained a Buy rating on Pharming Group (PHAR – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $9.77.
Singh covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Sarepta Therapeutics, and Biomea Fusion. According to TipRanks, Singh has an average return of 9.2% and a 43.92% success rate on recommended stocks.
Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $38.50.
PHAR market cap is currently $627M and has a P/E ratio of -63.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group (PHAR) Company Description:
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. Most of the revenue generated from the United States.
Read More on PHAR:
- Pharming Group’s Strategic Financial Maneuver
- Pharming Group Lauded for Rare Disease Treatment
- Pharming Completes Trial Enrollment for Pediatric Drug
- Joenja’s Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv
- Pharming Group Files Annual Report, Sets AGM Date
